Heart-Failure Therapy — New Drugs but Old Habits?

In 2015, empagliflozin, an inhibitor of sodium–glucose cotransporter 2 (SGLT2), lowered the composite cardiovascular end point in the EMPA-REG trial involving patients with type 2 diabetes mellitus who were at increased cardiovascular risk. What was remarkable in that finding was that the benefit…

Leave a Reply

Your email address will not be published. Required fields are marked *